Imbria Pharmaceuticals has randomised the first participant in FORTITUDE HCM, a Phase IIb trial of ninerafaxstat in ...

Advances development of ninerafaxstat, a potential first-in-class therapy designed to improve cardiac energetics in patients with serious cardiovascular diseases Enrollment underway across U.S. sites ...